Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- AstraZeneca
- Study ID
- NCT04550260
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Esophageal Squamous Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Durvalumab — DRUGDurvalumab intravenous infusion
- Placebo — DRUGDurvalumab matching placebo for intravenous infusion
- cisplatin + fluorouracil — DRUGcisplatin + fluorouracil, as per Standard of Care
- cisplatin + capecitabine — DRUGcisplatin + capecitabine, as per Standard of Care
- Radiation — RADIATION50-64Gy in total
Study Details
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).
Key Dates
- Start date
- Oct 19, 2020
- Status verified
- May 2026
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 640 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1: Durvalumab + definitive CRTDurvalumab + concurrent chemoradiation
- Placebo Comparator: Arm 2: Placebo + definitive CRTPlacebo + concurrent chemoradiation
Primary Outcome Measure
Progression free survival (PFS) per RECIST 1.1 as assessed by BICR [ Time Frame: up to approximately 56 months ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Atlanta | Georgia | 30308 | - |
| Research Site | Louisville | Kentucky | 40217 | - |
| Research Site | Dallas | Texas | 75390 | - |
| Research Site | Fairfax | Virginia | 22031 | - |
| Research Site | Morgantown | West Virginia | 26506 | - |
Find similar trials in Atlanta, GA
Related Studies
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Anchorage, Alaska
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Birmingham, Alabama
- A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerPHASE2 · Recruiting · VA Office of Research and Development · Palo Alto, California
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Beverly Hills, California